The Federal Commission for the Protection against Sanitary Risks (Cofepris) issued an updated health alert regarding the counterfeiting of Bayer medications from Mexico S.A. de C.V. In this new update, new counterfeit batches of Cafiaspirina, Desenfriol D, and Aspirina Protec have been identified. According to Bayer, these batches lack the appropriate active ingredients, which poses a serious health risk to consumers.
"As counterfeit products, they represent an imminent risk to the health of individuals who consume them, since the quality of the ingredients, manufacturing conditions, handling, storage, and distribution is unknown, and safety, quality, and efficacy are not guaranteed," stated the institution.
Cofepris' recommendation is clear: do not consume the mentioned batches, verify the authenticity with Bayer de Mexico, and report the sale of these counterfeit medications. They also urge to report any adverse reactions through the specified email address.
Distributors and pharmacies must ensure they purchase products only from authorized suppliers with sanitary licenses and legal documentation to avoid acquiring counterfeit medications. Cofepris will continue to monitor sanitary conditions and provide updates in case of new evidence.
Among the newly identified counterfeit batches are: Cafiaspirina (Acetylsalicylic Acid/Caffeine 500 mg/30 mg) with batch X23TJT, expiration March 2026; Desenfriol D (Chlorpheniramine/Phenylephrine/Paracetamol 2 mg/5 mg/500 mg) with batch X24EKH, expiration December 2026; and Aspirina Protec (Acetylsalicylic Acid 100 mg) with batch BT17US1/1, expiration August 2025.
These batches are added to those previously identified in the alert published on September 9, 2024. It is important to remember that these counterfeit products pose a danger to health, as the quality of their ingredients and manufacturing conditions is unknown.
